PolyPid (NASDAQ:PYPD) Posts Earnings Results, Beats Expectations By $0.12 EPS

PolyPid (NASDAQ:PYPD) issued its quarterly earnings data on Wednesday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.12, FiscalAI reports.

Here are the key takeaways from PolyPid’s conference call:

• PolyPid said its rolling NDA submission for D-PLEX100 is underway, with the remaining clinical module expected to be filed imminently, and that the product could qualify for priority review if the FDA accepts the submission.
• Management said U.S. strategic partnership discussions are in late stages, with the goal of supporting a commercial launch in Q1 2027 and prioritizing a partner with strong hospital sales capabilities.
• The company highlighted encouraging data from SHIELD II, including a 64% relative risk reduction in severe wound events, which it believes strengthens the product’s health-economic case for hospitals and payers.
• PolyPid said it is advancing its European MAA strategy and plans to submit the application to the EMA in the third quarter of 2026, subject to upcoming rapporteur meetings.
• Financially, the company reported a Q1 net loss of $7.7 million, cash and short-term deposits of $10.9 million at quarter-end, and said it fully repaid its remaining loan facility after quarter end, leaving it debt-free and funded into the second half of 2026.

PolyPid Trading Up 3.1%

Shares of NASDAQ:PYPD traded up $0.13 on Thursday, reaching $4.35. 56,228 shares of the company traded hands, compared to its average volume of 57,998. The business’s 50-day simple moving average is $4.38 and its 200 day simple moving average is $4.23. PolyPid has a 52 week low of $2.44 and a 52 week high of $5.12. The stock has a market capitalization of $83.00 million, a P/E ratio of -1.94 and a beta of 1.41.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its stake in shares of PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after buying an additional 3,500 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of PolyPid during the fourth quarter valued at about $44,000. Jane Street Group LLC bought a new position in shares of PolyPid during the fourth quarter valued at about $66,000. XTX Topco Ltd grew its stake in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after buying an additional 10,888 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in shares of PolyPid during the fourth quarter valued at about $451,000. 26.47% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a research report on Wednesday, February 11th. Weiss Ratings cut PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Finally, Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.